16 results
8-K
EX-99.1
DAWN
Day One Biopharmaceuticals Inc
26 Feb 24
Day One Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Progress
4:30pm
for the approval and launch of tovorafenib with the hiring of 18 sales representatives in the U.S.
The pivotal Phase 3 FIREFLY-2/LOGGIC clinical
8-K
EX-14.1
DAWN
Day One Biopharmaceuticals Inc
8 Dec 23
Amendments to the Registrant's Code of Ethics, or Waiver of a Provision of the Code of Ethics
4:05pm
that could present potential conflicts of interest and should be disclosed:
Hiring Related Parties: Hiring or supervising family members or others … employment opportunities for all applicants and employees. We do not unlawfully discriminate in employment opportunities (such as hiring or promotions
8-K
EX-99.1
DAWN
Day One Biopharmaceuticals Inc
6 Nov 23
Day One Reports Third Quarter 2023 Financial Results and Corporate Progress
4:30pm
a Priority Review and set a PDUFA date of April 30. Our commercial launch preparation is fully underway, including the hiring of a national sales force
PRE 14A
bml188iosxzoabo9nobz
18 Apr 23
Preliminary proxy
4:05pm
DEF 14A
mik0gheoehp
28 Apr 22
Definitive proxy
4:44pm
10-K
5rwv9 m0a4p9rgybm4
7 Mar 22
Annual report
7:36am
10-Q
r2acq8pr 2njw6
10 Aug 21
Quarterly report
5:26pm
424B4
slczpcqqcn01col
27 May 21
Prospectus supplement with pricing info
4:18pm
S-1/A
nllffaibewx s57
24 May 21
IPO registration (amended)
6:16am
S-1
4ee8txt63kre6h
4 May 21
IPO registration
4:12pm
DRS
b5yfp64f
19 Mar 21
Draft registration statement
12:00am
- Prev
- 1
- Next